Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Jan;63(1):19-26.
doi: 10.1111/j.1742-1241.2008.01911.x.

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

P Bergmann  1 , J-J Body, S Boonen, Y Boutsen, J-P Devogelaer, S Goemaere, J-M Kaufman, J-Y Reginster, V Gangji; Members of Advisory Board on Bone Markers
Affiliations
Free PMC article
Review

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

P Bergmann et al. Int J Clin Pract. 2009 Jan.
Free PMC article

Abstract

Objectives: To review the clinical value of bone turnover markers (BTM), to initiate and/or monitor anti-resorptive treatment for osteoporosis compared with bone mineral density (BMD) and to evaluate suitable BTM and changes in BTM levels for significance of treatment efficiency.

Methodology: Consensus meeting generating guidelines for clinical practice after review and discussion of the randomised controlled trials or meta-analyses on the management of osteoporosis in postmenopausal women.

Results: Although the correlation between BMD and BTM is statistically significant, BTM cannot be used as predictive markers of BMD in an individual patient. Both are independent predictors of fracture risk, but BTM can only be used as an additional risk factor in the decision to treat. Current data do not support the use of BTM to select the optimal treatment. However, they can be used to monitor treatment efficiency before BMD changes can be evaluated. Early changes in BTM can be used to measure the clinical efficacy of an anti-resorptive treatment and to reinforce patient compliance.

Discussion: Determining a threshold of BTM reflecting an optimal long-term effect is not obvious. The objective should be the return to the premenopausal range and/or a decrease at least equal to the least significant change (30%). Preanalytical and analytical variability of BTM is an important limitation to their use. Serum C-terminal cross-linked telopeptide of type I collagen (CTX), procollagen 1 N terminal extension peptide and bone specific alkaline phosphatase (BSALP) appear to be the most suitable.

Conclusion: Consensus regarding the use of BTM resulted in guidelines for clinical practice. BMD determines the indication to treat osteoporosis. BTM reflect treatment efficiency and can be used to motivate patients to persist with their medication.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med. 1993;94:646–50. - PubMed
    1. Van Hoof VO, Hoylaerts MF, Geryl H, et al. Age and sex distribution of alkaline phosphatase isoenzymes by agarose electrophoresis. Clin Chem. 1990;36:875–8. - PubMed
    1. Broyles DL, Nielsen RG, Bussett EM, et al. Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem. 1998;44:2139–47. - PubMed
    1. Gundberg CM, Markowitz ME, Mizruchi M, et al. Osteocalcin in human serum: a circadian rhythm. J Clin Endocrinol Metab. 1985;60:736–9. - PubMed
    1. Delmas PD, Wilson DM, Mann KG, et al. Effect of renal function on plasma levels of bone Gla-protein. J Clin Endocrinol Metab. 1983;57:1028–30. - PubMed

Publication types